MENU
THNR
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

THNR stock forecast, quote, news & analysis

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for THNR with price predictions
Nov 11, 2026

THNR's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for THNR turned positive on October 19, 2026. Looking at past instances where THNR's MACD turned positive, the stock continued to rise in 20 of 22 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on THNR as a result. In 30 of 37 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.

THNR moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for THNR crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Following a +4.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where THNR advanced for three days, in 111 of 132 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Bearish Trend Analysis

The 10-day RSI Indicator for THNR moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 13 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 24 of 29 cases where THNR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where THNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

THNR broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for THNR entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Regeneron Pharmaceuticals (NASDAQ:REGN), Arrowhead Pharmaceuticals (NASDAQ:ARWR).

Industry description

The investment seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies expected to economically benefit from weight loss drug development. The index includes pharmaceutical manufacturers, manufacturers of combination therapies and telehealth providers who provide access to Amylin agonists and analogs or GLP-1 agonists and analogs, including dual GLP-1 agonists and analogs. The fund is non-diversified.

Market Cap

The average market capitalization across the Amplify Weight Loss Drug & Treatment ETF (THNR) ETF is 174.55B. The market cap for tickers in the group ranges from 1.45B to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is GPCR at 1.45B.

High and low price notable news

The average weekly price growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF (THNR) ETF was -2%. For the same ETF, the average monthly price growth was 6%, and the average quarterly price growth was 4%. KLRA experienced the highest price growth at 12%, while ARWR experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Amplify Weight Loss Drug & Treatment ETF (THNR) ETF was -30%. For the same stocks of the ETF, the average monthly volume growth was 36% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 42
Price Growth Rating: 41
SMR Rating: 68
Profit Risk Rating: 64
Seasonality Score: 25 (-100 ... +100)